Kazia Therapeutics enters one of world's largest pharma markets through Chinese licensing deal for paxalisib with Simcere PharmaceuticalProactive Investors • 03/29/21
Kazia Therapeutics Stock Is Trading Higher On Paxalisib Licensing Agreement In Greater ChinaBenzinga • 03/29/21
Kazia Therapeutics in trading halt with regional licensing transaction news pendingProactive Investors • 03/26/21
Kazia Therapeutics CEO and MD highlights 2021 progress with focus on providing treatment for diagnosed glioblastomaProactive Investors • 03/18/21
Kazia Therapeutics grants Oasmia exclusive rights for first-in-class ovarian cancer drug candidate CantrixilProactive Investors • 03/01/21
Kazia Therapeutics achieves key half-year milestones and ends period with cash balance of $19.4 millionProactive Investors • 02/25/21